These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

395 related items for PubMed ID: 17916462

  • 1. Cell based cancer vaccines: regulatory and commercial development.
    Copier J, Ward S, Dalgleish A.
    Vaccine; 2007 Sep 27; 25 Suppl 2():B35-46. PubMed ID: 17916462
    [Abstract] [Full Text] [Related]

  • 2. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G, Cancer Vaccine Clinical Trial Working Group.
    J Immunother; 2007 Jan 27; 30(1):1-15. PubMed ID: 17198079
    [Abstract] [Full Text] [Related]

  • 3. Design of clinical trials for therapeutic cancer vaccines development.
    Mackiewicz J, Mackiewicz A.
    Eur J Pharmacol; 2009 Dec 25; 625(1-3):84-9. PubMed ID: 19835869
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Recombinant viral vectors: cancer vaccines.
    Harrop R, John J, Carroll MW.
    Adv Drug Deliv Rev; 2006 Oct 01; 58(8):931-47. PubMed ID: 17030074
    [Abstract] [Full Text] [Related]

  • 11. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
    Gray A, Raff AB, Chiriva-Internati M, Chen SY, Kast WM.
    Immunol Rev; 2008 Apr 01; 222():316-27. PubMed ID: 18364011
    [Abstract] [Full Text] [Related]

  • 12. Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials.
    Mosolits S, Nilsson B, Mellstedt H.
    Expert Rev Vaccines; 2005 Jun 01; 4(3):329-50. PubMed ID: 16026248
    [Abstract] [Full Text] [Related]

  • 13. Cancer vaccines: a critical review on clinical impact.
    Bitton RJ.
    Curr Opin Mol Ther; 2004 Feb 01; 6(1):17-26. PubMed ID: 15011777
    [Abstract] [Full Text] [Related]

  • 14. Characterization of polyvalent allogeneic vaccines.
    Van Epps D.
    Dev Biol (Basel); 2004 Feb 01; 116():79-90; discussion 133-43. PubMed ID: 15603185
    [Abstract] [Full Text] [Related]

  • 15. Cancer vaccines for established cancer: how to make them better?
    Andrews DM, Maraskovsky E, Smyth MJ.
    Immunol Rev; 2008 Apr 01; 222():242-55. PubMed ID: 18364006
    [Abstract] [Full Text] [Related]

  • 16. Cancer vaccines and immunotherapies: emerging perspectives.
    Henderson RA, Mossman S, Nairn N, Cheever MA.
    Vaccine; 2005 Mar 18; 23(17-18):2359-62. PubMed ID: 15755628
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Challenges for cancer vaccine development.
    Tabi Z, Man S.
    Adv Drug Deliv Rev; 2006 Oct 01; 58(8):902-15. PubMed ID: 16979786
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [New advances in clinical trials of cancer vaccines].
    Peng F, Wei YQ.
    Ai Zheng; 2006 Aug 01; 25(8):1059-62. PubMed ID: 16965694
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.